- ICH GCP
- Registro de ensaios clínicos dos EUA
- Ensaio Clínico NCT04400695
Um estudo de RC48-ADC para o tratamento de câncer de mama localmente avançado ou metastático com baixa expressão de HER2
Estudo clínico randomizado, controlado e multicêntrico de fase III avaliando a eficácia e a segurança do RC48-ADC para o tratamento de câncer de mama localmente avançado ou metastático com baixa expressão de HER2
This study will compare RC48-ADC to physician choice standard treatment. Participants must have HER2-low breast cancer ,previous use of anthracyclines, and have been treated with one or two systemic chemotherapy regimens following recurrence/metastasis.
Visão geral do estudo
Status
Condições
Descrição detalhada
This study is a multi-center, randomized, open, parallel control to evaluate the effectiveness and safety of Phase III clinical trials of the efficacy and safety of recombinant humanized anti-HER2 monoclonal antibody-Monomethyl auristatin E (MMAE) conjugate for the treatment of locally advanced or metastatic breast cancer the study.The low expression of HER2 is defined as: the immunohistochemistry (IHC) confirmed by the central laboratory detects the expression of HER2 protein as IHC 2+ and the fluorescence in situ hybridization (FISH) detection has no amplification.
Tipo de estudo
Inscrição (Estimado)
Estágio
- Fase 3
Contactos e Locais
Contato de estudo
- Nome: Binghe Xu, M.D.
- Número de telefone: 010-87788826
- E-mail: bhxu@hotmail.com
Locais de estudo
-
-
Beijing Municipality
-
Beijing, Beijing Municipality, China, 100021
- Recrutamento
- Oncology Hospital, Chinese Academy of Medical Sciences
-
Contato:
- Binghe Xu
- Número de telefone: 010-87788826
- E-mail: bhxu@hotmail.com
-
-
Critérios de participação
Critérios de elegibilidade
Idades elegíveis para estudo
Aceita Voluntários Saudáveis
Gêneros Elegíveis para o Estudo
Descrição
Inclusion Criteria:
- Voluntarily agree to participate in the study and sign the informed consent;
- Subjects aged 18-70 years (including 18 years and 70 years) and not reaching the 71st birthday were all considered to be ≤70 years old;
- Expected survival ≥12 weeks;
- Eastern Cooperative Oncology Group(ECOG) physical condition 0 or 1;
- For female subjects of child-bearing age women agreed to study during treatment and experimental subjects within 6 months after the end of the treatment period using an approved by the medical contraception (e.g. intrauterine device, the pill or condoms), before the study drug delivery within 7 days of pregnancy blood test must be negative (sterilization surgery or age 60 or more subjects can choose no pregnancy blood test), and must be an lactation. For male subjects: should be sterilized surgically, or agree to use a medically approved contraceptive method during the study period and for 6 months after the end of the treatment period. Control subjects after the end of the treatment period according to the choice of control drugs to determine the length of contraception.
- Able to understand the study requirements and be willing and able to follow the study and follow-up procedures.
- Bone marrow function:
hemoglobin ≥9g/dL; absolute neutrophil count ≥1.5×109/L; white blood cell count ≥3.0×109/L platelet ≥100 ×109/L;
- Liver function (according to the normal value of the clinical trial center) :
serum total bilirubin ≤1.5 times the upper limit of normal value (ULN); alanine aminotransferase (ALT), aspartate aminotransferase(AST) and Alkaline phosphatase(ALP) were ≤2.5 × ULN in the absence of liver metastasis, and ALT, AST and Alkaline phosphatase(ALP) were ≤5 × ULN in the presence of liver metastasis
- Renal function (according to the normal value of the clinical trial center) :
serum creatinine ≤1.5×ULN, or calculated by Cockcroft-Gault formula, the creatinine clearance rate (CrCl) ≥60 mL/min;
- Cardiac function:
American New York college of cardiology (NYHA) grade < 3; left ventricular ejection fraction ≥50%;
- Breast cancer subjects diagnosed by histology and / or cytology are currently at a locally advanced or metastatic stage and cannot be radically removed;
- The low expression of HER2 confirmed by the IHC and FISH results of the central laboratory (defined as: IHC 2+ and no amplification of FISH); the subject can provide a specimen of the primary or metastatic tumor site (paraffin wax) for HER2 detection Block, paraffin-embedded section or fresh tissue section can be used);
- Previous use of anthracycline drugs;
- Received 1 or 2 systemic chemotherapy treatments after relapse / metastasis. Subjects who relapsed during adjuvant chemotherapy or within 12 months after the end of adjuvant chemotherapy were considered to have failed first-line chemotherapy after relapse / metastasis.
- Hormone receptors are negative or positive. Hormone receptor-positive subjects need to progress after receiving endocrine therapy after relapse / metastasis or relapse after less than 2 years. Patients who are not suitable for endocrine therapy can be included in this study after undergoing chemotherapy treatment (first-line or second-line);
- The imaging evidence confirmed by the investigator that the tumor disease progressed during or after the most recent treatment is required;
- There has been no diagnosis of HER2 positive (HER2 IHC 3+ or FISH amplification)
- Have not used drugs targeting HER2 (including antibodies, small molecule Tyrosine kinase inhibitor(TKIs) and antibody drug conjugates).
- According to the RECIST 1.1 standard, there is at least one measurable lesion.
Exclusion Criteria:
- Received chemotherapy within 4 weeks before the start of study administration (treatment with nitrosourea and mitomycin C within 6 weeks, oral fluorouracil within 2 weeks), radiotherapy (palliative for bone metastases Local radiotherapy is within 2 weeks before study administration), immunotherapy; received endocrine therapy for breast cancer within 2 weeks before study administration;
- The research drug was used within 4 weeks before the start of study administration;
- Have undergone major surgery within 4 weeks before the start of study administration;
- Have received a live vaccine within 4 weeks before the start of study administration or plan to receive any vaccine during the study period;
- Serious cardiovascular and cerebrovascular events occurred within 12 months, including but not limited to unstable angina, myocardial infarction, cerebral hemorrhage, and cerebral infarction (except for asymptomatic and untreated lacunar infarction);
- Those who are suffering from heart disease are not suitable for enrollment, including but not limited to arrhythmia and heart failure requiring medical treatment or accompanied by symptoms;
- There are other lung diseases requiring treatment or serious, including but not limited to active pulmonary tuberculosis, interstitial lung disease, etc ;
- Suffering from active infection requiring systemic treatment;
- Have active autoimmune diseases (such as the use of corticosteroids or immunosuppressive drugs, etc.) that require systemic treatment within the past 2 years, allowing related alternative treatments (such as thyroxine, insulin, or the physiology of adrenal or pituitary insufficiency Corticosteroid replacement therapy);
- The toxicity of the previous anti-tumor therapy has not been restored to the 0 to 1 level defined by CTCAE version 5.0, of which the neurotoxicity has not been restored to 0; except for hair loss, pigmentation or other researches that do not increase the risk of medication Happening;
- Have a clear past or current history of neurological or mental disorders, including epilepsy or dementia;
- According to the investigator's judgment, there are concomitant diseases that seriously endanger the safety of the subject or affect the completion of the clinical study;
- Positive HIV test results; patients with active hepatitis B or C (HBsAg positive and hepatitis B virus(HBV) DNA titers above the upper limit of normal; Hepatitis C Virus Antibody(HCVAb) positive hepatitis C virus (HCV) RNA titers above the upper limit of normal);
- There is a third interstitial fluid that cannot be controlled by drainage or other methods (including a large amount of pleural effusion or ascites);
- Known hypersensitivity or delayed allergic reaction to certain components of RC48-ADC or similar drugs;
- Subjects who are not suitable for using any of the alternative control drugs;
- The presence of brain metastases and / or cancerous meningitis;
- Have other malignant tumors within 5 years before signing the informed consent form (except for non-melanoma skin cancer, cervical carcinoma in situ or other tumors that have been effectively treated, except malignant tumors that are considered cured);
- Subjects who are estimated to be inadequate for patients to participate in this clinical study or other factors that the investigator believes are inappropriate to participate in this study;
Plano de estudo
Como o estudo é projetado?
Detalhes do projeto
- Finalidade Principal: Tratamento
- Alocação: Randomizado
- Modelo Intervencional: Atribuição Paralela
- Mascaramento: Nenhum (rótulo aberto)
Armas e Intervenções
Grupo de Participantes / Braço |
Intervenção / Tratamento |
|---|---|
|
Experimental: RC48-ADC
RC48-ADC common name:Recombinant Humanized anti-HER2 Monoclonal Antibody-MMAE Conjugate For Injection Dosage form:Lyophilized powder injection specification:60 mg / piece Medication plan:Every 2 weeks Expiration date:18 months HER2-low, unresectable, locally advanced or metastatic breast cancer participants previously treated with anthracycline and received 1 or 2 systemic chemotherapy after relapse / metastasis. |
RC48-ADC 2.0mg / kg, intravenous drip, once every 2 weeks
Outros nomes:
|
|
Comparador Ativo: Physician's Choice
Physician's Choice: HER2-low, unresectable, locally advanced or metastatic breast cancer participants previously treated with anthracycline and received 1 or 2 systemic chemotherapy after relapse / metastasis. Physician's choice from the following options: Paclitaxel Injection Docetaxel Injection Vinorelbine Tartrate Injection Capecitabine Tablets |
Administered according to label, as one option for Physician's Choice (determined before randomization)
Outros nomes:
Administered according to label, as one option for Physician's Choice (determined before randomization)
Outros nomes:
Administered according to label, as one option for Physician's Choice (determined before randomization)
Outros nomes:
Administered according to label, as one option for Physician's Choice (determined before randomization)
Outros nomes:
|
O que o estudo está medindo?
Medidas de resultados primários
Medida de resultado |
Descrição da medida |
Prazo |
|---|---|---|
|
Progression-free survival (PFS), evaluated by an independent efficacy evaluation committee
Prazo: within approximately 3 years
|
Progression-free survival (PFS) refers to the time from the date of randomization to the first researcher's evaluation of disease progression or death (calculated by the event that occurred first). The disease progression will be evaluated by the researchers according to the RECIST 1.1 standard. |
within approximately 3 years
|
Medidas de resultados secundários
Medida de resultado |
Descrição da medida |
Prazo |
|---|---|---|
|
Progression-free survival (PFS), evaluated by the investigator
Prazo: within approximately 3 years
|
Progression-free survival (PFS) refers to the time from the date of randomization to the first researcher's evaluation of disease progression or death (calculated by the event that occurred first). The disease progression will be evaluated by the researchers according to the RECIST 1.1 standard. |
within approximately 3 years
|
|
Objective remission rate (ORR)
Prazo: within approximately 3 years
|
The objective response rate will be mainly analyzed by the independent efficacy evaluation committee according to the RECIST 1.1 standard tumor evaluation (the evaluation by the investigator will also be performed). |
within approximately 3 years
|
|
Duration of relief (DOR)
Prazo: within approximately 3 years
|
DOR is defined as the time from the first documented objective response (CR or PR) to the first documented disease progression or death |
within approximately 3 years
|
|
Disease control rate (DCR)
Prazo: within approximately 3 years
|
Disease control rate (DCR) is defined as cases where objective remission (assessed as complete remission or partial remission according to RECIST 1.1 standard) or stable disease during the study. |
within approximately 3 years
|
|
Tumor progression time (TTP)
Prazo: within approximately 3 years
|
Time to disease progression (TTP) refers to the time from the random date to the first disease progression (calculated by the event that occurred first). Disease progression will be evaluated by the investigator according to the RECIST 1.1 standard (investigator and Independent Review Committee(IRC) evaluation). |
within approximately 3 years
|
|
Overall survival (OS)
Prazo: within approximately 3 years
|
Overall survival (OS) refers to the time from the date of randomization to the date of death of the subject. |
within approximately 3 years
|
Colaboradores e Investigadores
Patrocinador
Investigadores
- Investigador principal: Yu Jiang, West China Hospital
- Investigador principal: Binghe Xu, Oncology Hospital, Chinese Academy of Medical Sciences
- Investigador principal: Wei Li, Jilin University First Hospital
- Investigador principal: Xiaojia Wang, Zhejiang Cancer Hospital
- Investigador principal: Ying Wang, Sun Yat-sen University Cancer Prevention and Control Center
- Investigador principal: Ning Liao, Guangdong Provincial People's Hospital
- Investigador principal: Haibo Wang, Qingdao University Hospital
- Investigador principal: Quchang Ouyang, Hunan Cancer Hospital
- Investigador principal: Yueyin Pan, Anhui Provincial Hospital
- Investigador principal: Yingying Du, The First Affiliated Hospital of Anhui Medical University
- Investigador principal: Jin Yang, The First Affiliated Hospital of Xi'an Jiaotong University School of Medicine
- Investigador principal: Xiuwen Wang, Qilu Hospital of Shandong University
- Investigador principal: Huihua Xiong, Tongji Hospital
- Investigador principal: Xinhong Wu, Hubei Cancer Hospital
- Investigador principal: Weimin Xie, Cancer Hospital Affiliated to Guangxi Medical University
- Investigador principal: Xin Zhou, Chongqing University Cancer Hospital
- Investigador principal: Li Ran, Cancer Hospital of Guizhou Province
- Investigador principal: Yu Wang, Shanxi Province Cancer Hospital
- Investigador principal: Jinnan Gao, Bethune Hospital of Shanxi Province
- Investigador principal: Jingfen Wang, Linyi Cancer Hospital
- Investigador principal: Xianhe Xie, First Affiliated Hospital of Fujian Medical University
- Investigador principal: Ru Zeng, The First Affiliated Hospital of Xiamen University
- Investigador principal: Airong Wang, Weihai Municipal Hospital
- Investigador principal: Zhengqiu Zhu, The Affiliated Hospital of Xuzhou Medical University
- Investigador principal: Sanyuan Sun, Xuzhou Central Hospital
- Investigador principal: Qingshan Li, Affiliated Hospital of Chengde Medical College
- Investigador principal: Aimin Zang, Affiliated Hospital of Hebei University
- Investigador principal: Liuzhong Yang, The First Affiliated Hospital of Xinxiang Medical College
- Investigador principal: Meili Sun, Jinan Central Hospital
- Investigador principal: Liang Li, Zibo Central Hospital
- Investigador principal: Guohua Yu, Weifang People's Hospital
- Investigador principal: Xujuan Wang, Neijiang Second People's Hospital
- Investigador principal: Ying Wang, Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
- Investigador principal: Ying Cheng, Jilin Provincial Tumor Hospital
- Investigador principal: Jifeng Feng, Jiangsu Cancer Institute & Hospital
- Investigador principal: Tao Sun, Liaoning Cancer Hospital & Institute
- Investigador principal: Yuee Teng, First Hospital of China Medical University
- Investigador principal: Shu Wang, Peking University People's Hospital
- Investigador principal: Min Yan, Henan Cancer Hospital
- Investigador principal: Changlu Hu, Anhui Provincial Cancer Hospital
- Investigador principal: Zhongsheng Tong, Tianjin Cancer Hospital Airport Hospital
- Investigador principal: Lihua Song, Shandong Cancer Hospital and Institute
- Investigador principal: Yunjiang Liu, Hebei Medical University Fourth Hospital
- Investigador principal: Jing Cheng, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
- Investigador principal: Peng Shen, First Affiliated Hospital of Zhejiang University
- Investigador principal: Liangming Zhang, Yantai Yuhuangding Hospital
Datas de registro do estudo
Datas Principais do Estudo
Início do estudo (Real)
Conclusão Primária (Estimado)
Conclusão do estudo (Estimado)
Datas de inscrição no estudo
Enviado pela primeira vez
Enviado pela primeira vez que atendeu aos critérios de CQ
Primeira postagem (Real)
Atualizações de registro de estudo
Última Atualização Postada (Real)
Última atualização enviada que atendeu aos critérios de controle de qualidade
Última verificação
Mais Informações
Termos relacionados a este estudo
Termos MeSH relevantes adicionais
- Neoplasias por local
- Neoplasias
- Doenças de pele
- Doenças da mama
- Doenças da Pele e do Tecido Conjuntivo
- Neoplasias da Mama
- Produtos químicos orgânicos
- Compostos heterocíclicos, 1 anel
- Compostos heterocíclicos
- Compostos heterocíclicos, 2 anel
- Compostos heterocíclicos, anel fundido
- Ácidos nucleicos, nucleotídeos e nucleosídeos
- Hidrocarbonetos
- Cicloparaffinas
- Hidrocarbonetos, aliciclicos
- Hidrocarbonetos, cíclicos
- Terpenos
- Alcalóides
- Indoles
- Taxóides
- Ciclodecanos
- Diterpenos
- Desoxicitidina
- Citidina
- Nucleosídeos de pirimidina
- Pirimidinas
- Nucleosídeos
- Uracil
- Pirimidinonas
- Alcalóides de Vinca
- Alcalóides de triptamina de secologanin
- Alcalóides indol
- Indolizidinas
- Indolizinas
- Desoxirribonucleosídeos
- Fluorouracil
- Docetaxel
- Capecitabina
- Vinorelbina
- Paclitaxel
Outros números de identificação do estudo
- RC48-C012
Plano para dados de participantes individuais (IPD)
Planeja compartilhar dados de participantes individuais (IPD)?
Informações sobre medicamentos e dispositivos, documentos de estudo
Estuda um medicamento regulamentado pela FDA dos EUA
Estuda um produto de dispositivo regulamentado pela FDA dos EUA
Essas informações foram obtidas diretamente do site clinicaltrials.gov sem nenhuma alteração. Se você tiver alguma solicitação para alterar, remover ou atualizar os detalhes do seu estudo, entre em contato com register@clinicaltrials.gov. Assim que uma alteração for implementada em clinicaltrials.gov, ela também será atualizada automaticamente em nosso site .